A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis.

Trial Profile

A Phase II Randomised, Double-Blind, Placebo-Controlled, Parallel Group Study to Assess the Efficacy of 28-Day Oral Administration of AZD5069 Twice Daily in Patients With Bronchiectasis.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2015

At a glance

  • Drugs AZD 5069 (Primary)
  • Indications Bronchiectasis
  • Focus Therapeutic Use
  • Acronyms STRATUS
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Oct 2015 Primary end point and time frame has been changed as reported by ClinicalTrials.gov record.
    • 08 Sep 2013 Primary endpoint 'Neutrophil-count' has been met.
    • 08 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top